Paul Herendeen

Analysts at Cantor Fitzgerald turned incrementally bullish on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) after the once-troubled pharmaceutical company is showing signs of sustaining momentum. Cantor Fitzgerald's Louise Chen maintains an Overweight rating on Valeant's stock with a price...

Morgan Stanley has slashed its price target on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares by $17 to $25, saying it underestimated generic pressures on the company's older franchises and the risk of an ex-U.S. franchise slowdown. The latest action follows Valeant’s poor third-...